Wednesday, May 23, 2012

Yaffe: Taiwan’s diminished status sign of China’s growing clout

By Barbara Yaffe, Vancouver Sun May 22, 2012   What's in a name? A great deal, in the opinion of Taiwan, fighting this week for a rightful place at World Health Organization meetings in Geneva.   Taiwan has been newly relegated to the status of "a province of China" at the sessions, instead of its traditional and more respectful designation, "Chinese Taipei."   Canada has long supported the island nation's participation at international assemblies, recognizing that Taiwan — the world's 18th largest economy and a democracy — has much to offer the global community.   Canada also has robust Taiwanese communities in Vancouver and Toronto, totalling some 160,000 people.   But in Geneva, where the World Health Assembly is meeting until Saturday, a tussle continues to play out between China, which claims Taiwan is an integral part of its territory, and Taiwan itself, which has existed separate and apart from the mainland since 1949. The WHA is the governing body of the UN's World Health Organization.   Taiwan, which runs its own affairs and collects taxes from its citizens, wishes to remain separate from China. Indeed, many Taiwanese want their lush, tropical island of 23 million — known for its exquisite bird life and bountiful orchid crop — to be a fully independent country.   But the government, quite legitimately, fears a backlash from China should it advance that cause. And so Taipei has been pragmatic, lying low and seeking to content itself with observer status at global gatherings such as the WHA. "Chinese Taipei" has sat in on WHA meetings as an observer since 2009, during which time relations with China have improved. The recently reelected government of Ma Ying-jeou in Taipei is continuing to foster greater economic ties with the mainland.   But this week, Taiwan's Health Minister Chiu Wen-ta expressed "grave concern" over his country's new designation, which clearly serves to advance the concept of Taiwan's subservience to China. "Taiwan," he declared, "does not need to go through China when it needs to make contact with the World Health Organization."   Chiu also expressed concern that in the past year Taiwan has been blocked from participating in nine of 21 WHO working panels.   Canada finds itself in an awkward place between China and Taiwan. While this country has often espoused the right of self-determination, certainly in relation to Quebec, and has generally supported Taiwanese aspirations, ministers in the Harper government have been reluctant to speak on Taiwan's behalf because China has become so important economically to Canada.   The fuss over Taiwan's name at the WHA is ironic because the small country has become a beacon in the field of health care.   It set up a universal single-payer health care system nearly 20 years ago, with 99 per cent of citizens fully covered for everything from home care to rehabilitation services to dental care.   Yet, Taiwan spends just 6.9 per cent of its GDP on health care — compared to 11.6 per cent spent last year in Canada.   Taiwan is a medical technology leader. "We have developed world-class expertise in biochips, biomedical materials, biomedical informatics and both medical and pharmaceutical engineering," says a Taiwanese health department document. Taiwan is a specialist in electronic medical record management and distance health care.  "Taiwan's participation in global health affairs will benefit people in Taiwan and around the world," asserts Osman Chia, a Taiwanese diplomat in Vancouver.   The latest WHA kerfuffle points to a much larger challenge for Taiwan — how such a small and worthy democracy can garner necessary support for its cause from other nations when those other nations are so fearful of damaging trade relations with the Chinese behemoth.

Folic acid tied to lower child cancer risks

Tuesday, May 22, 2012   By Amy Norton  NEW YORK (Reuters Health) - Rates of two rare childhood cancers declined after the U.S. began requiring grain products to be fortified with the B vitamin folic acid, a new study finds.  Reported in the journal Pediatrics, the study does not prove that folic acid deserves the credit.  But researchers say the findings at least offer reassurance that folic-acid fortification has not led to an increase in children's cancers -- which has been a theoretical concern.  "The good news is that there doesn't seem to have been an increased risk of childhood cancer," said lead researcher Amy M. Linabery, of the University of Minnesota in Minneapolis.  In 1996, the U.S. mandated that enriched flours, breads, pastas and other grain products be fortified with folic acid, the synthetic version of the B vitamin folate.  The goal was to help reduce rates of neural tube defects, severe birth defects of the brain and spine. They include spina bifida, when the spine fails to close during early fetal development, and anencephaly -- usually fatal -- when much of the brain never forms.  Experts advise women of childbearing age to get 400 micrograms of folic acid per day, and urge them to establish that level of intake before conception, since neural tube defects take shape very early, before many women know they are pregnant.  Some other countries, though, are still debating whether to add folic acid to the grain supply. One concern has been the vitamin's potential to contribute to cancer; some research has linked folic-acid fortification to an increased rate of colon cancer in adults.  But no one knows if folic acid is to blame. In fact, other research has tied higher intakes of folate from food to a lower risk of colon cancer.  Since women should already be getting folate and folic acid to curb the risk of birth defects, these latest findings should offer them some reassurance that it's safe as far as their future children's cancer risk, according to Linabery.  For their study, Linabery and her colleagues used government data on cancer rates among children younger than five between 1986 and 2008.  Over those years, 8,829 children were diagnosed with cancer. Overall, cancer rates were similar before and after mandatory folic-acid fortification.  But for two cancers, the rates dipped in the folic-acid era, compared with the decade before.  Wilms tumor, a type of kidney cancer, dipped from about 18 cases for every one million children each year, to just under 15 cases per million.  The other cancer, known as a primary neuroectodermal tumor, declined from roughly four cases per one million each year, to just over two cases per million.  Both cancers are quite rare, and no one is suggesting that women take folic acid to prevent the diseases in their children.  "But we already believe that women should be getting folic acid for the proven benefit of preventing neural tube defects," Linabery said.  The study has limitations. It looked at overall national patterns -- and not the relationship between a woman's actual folic acid intake and her child's individual risk of cancer.  Still, Linabery said, "taking folic acid during the childbearing years is important." And these findings, she added, offer reassurance that fortification has not led to any increases in childhood cancer in the U.S. 

SOURCE: http://bit.ly/K66UN8 Pediatrics, online May 21, 2012.   

Taiwan unveils new orchid species for use as Chinese medicine

2012/05/23    Taipei, May 23 (CNA) The Council of Agriculture (COA) on Wednesday unveiled a new orchid species for use in traditional Chinese medicine, saying it took eight years to breed and contains high levels of polysaccharides that are good for people in chemotherapy.   The Golden Emperor No. 1, a crossbreed between dendrobium tosaense and dendrobium stem, contains more polysaccharides than the premium orchid species dendrobium huoshanense that originated in China's Anhui Province, the council said.   Polysaccharides play a role in stimulating the immune system and can aid the recovery of patients in chemotherapy, said Wen Chi-luan, a research assistant at the council's Taiwan Seed Improvement and Propagation Station.   Patients recovering from eye surgery can also benefit from polysaccharides, as they activate the retinal cell layers, Wen said.   Golden Emperor No. 1, to be mass produced soon, will take only two years to grow and will yield 8 to 12 grams of dried polysaccharides annually, he said.   In other words, the new species matures in half the time as the premium orchid species dendrobium houshanense and its yield is five times higher, Wen added.   One of the most expensive types of orchids in Chinese medicine, 600 grams of dried dendrobium huoshanense herbal medicine can cost NT$8,900 (US$300).   Dendrobium orchids are recorded as a high class Chinese medicine, similar to ginseng, in the traditional Chinese medical journal "the Divine Farmer's Herb-Root Classic," which was written by legendary ruler Shengnong some 5,000 years ago, Wen noted.   Some medical uses of dendrobium orchids recorded in the journal include a cure for dryness, thirst and inflammation, protection of the stomach, cleansing of the liver, and improvement of eyesight, Wen said.  

Novartis calls students to participate in BioCamp at Hyderabad from July 30

 Wednesday, May 23, 2012,     Novartis India is conducting Novartis Biotechnology Leadership Camp (BioCamp) at Hyderabad from July 30 to August 1, 2012 and invited students to participate from 100 Indian universities. BioCamp is a pioneering seminar organized by Novartis that brings young, talented students from diverse faculties and different universities closer to the pharmaceutical industry.    BioCamp is open to postgraduate students and young researchers in natural sciences, medicine, biotechnology, bio-informatics, pharmacy, business administration or law (specialization in Intellectual Property Rights) interested in pursuing a career in the pharmaceutical/biotechnology industry. Last date for receiving applications is June 14, 2012.    Selected students will have the opportunity to learn from and network with leaders in the pharmaceutical/biotechnology and business sector as well as hone their team building skills.  The top three students from the India BioCamp will represent India at the International BioCamp being held at Novartis global headquarters in Basel, Switzerland from August 26 to 29, 2012.  Ranjit Shahani, vice chairman & managing director, Novartis India Ltd said, "BioCamp offers an opportunity to young talented individuals to exchange views and thoughts with leaders in the pharmaceutical industry. It serves as a platform to bring young minds to think of making a positive contribution to changing the face of healthcare in India. BioCamp is an example of the Novartis commitment to supporting the student community and building relationships with academia to address the healthcare needs of our country."   Since launching the BioCamp initiative in 2004, Novartis has introduced nearly 500 top graduate students to the biotech industry and entrepreneurship. Besides regional events in various countries, global BioCamps have been held in Taiwan (2004), Singapore (2006), Tokyo (2007), Hong Kong (2008) and Cambridge, Massachusetts (2009) and since then in Basel, Switzerland.  Interested students should visit www.novartis.in or email biocamp.india@novartis.com for more information.

Convierten células de la piel en células del músculo cardíaco

Martes, 22 mayo a las 20:07:51  Científicos israelíes han logrado convertir por primera vez células de la piel de enfermos del corazón en células sanas del músculo cardíaco y trasplantarlas con éxito a ratones, publica hoy la revista médica "European Heart Journal".  Según los investigadores, este logro supone un avance en la búsqueda de tratamientos que permitan curar el corazón de un paciente con sus propias células.  Estudios recientes sobre células madre e ingeniería de tejidos habían logrado reprogramar células de individuos jóvenes y sanos, pero hasta ahora no lo habían conseguido a partir de células de pacientes enfermos del corazón o personas de edad avanzada.  "Hemos demostrado que es posible extraer células de la piel de un paciente anciano con un fallo cardíaco avanzado" y transformarlas en "células sanas y jóvenes, el equivalente a cómo eran cuando nació el paciente", afirmó Lior Gepstein, investigador del Sohnis Research Laboratory israelí.  En concreto, los expertos de tres instituciones científicas de Haifa (Israel) obtuvieron células cutáneas de dos hombres de 51 y 61 años con fallo cardíaco, las reprogramaron en células cardíacas y consiguieron unirlas a una muestra de tejido cardíaco dañado en un plazo de 48 horas.  A continuación, los investigadores implantaron con éxito este tejido en el corazón de varios ratones sanos.  Gepstein considera que su técnica podrá superar dos de los principales obstáculos de este tipo de investigaciones: el riesgo de que una vez implantadas se conviertan en tumores y el rechazo por parte del sistema inmune del paciente.  El hecho de que las células reprogramadas procedan del mismo paciente al que se le van a implantar evitaría que el sistema inmune las considere "extrañas", aunque de momento no se ha trasplantado a seres humanos.  Los investigadores de los centros Sohnis Research Laboratory, el Technion-Israel Institute of Technology y el Ramban Medical Center advirtieron de que aún es necesario superar varios obstáculos para que estas terapias tengan éxito en humanos.  Con el fin de lograr un tratamiento apto para las personas "deberán pasar al menos entre cinco y diez años de ensayos clínicos a partir del momento en el que alguien logre superar todos los obstáculos que ahora presenta la investigación", añadió Gepstein.
alveice Team. Powered by Blogger.